BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37612600)

  • 1. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
    Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Xiao M; Li L; Zhu W; Wu F; Wu B
    Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
    Zhao D; Long X; Zhou J; Wang J
    Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
    Zhao D; Zhang W; Liu Y; Yan Z
    Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
    Zhao D; Long X; Wang J
    Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
    Ke C; Chen M; Huang Y; Chen Y; Lin C; Huang P
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5253-5264. PubMed ID: 38270617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system.
    Zhang W; Chen M; Cai X; Zhang M; Hu M; Hu Y; Yang Y; Zhu J; Du Y; Yang C
    Expert Opin Drug Saf; 2024 May; 23(5):617-625. PubMed ID: 38568141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
    Yun X; Zhou Y; Wu D; Liu Y; Wu Q
    Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
    Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
    Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
    Ren X; Wang H; Deng L; Wang W; Wang Y
    Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
    Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
    Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Chen W; Cai P; Zou W; Fu Z
    Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System.
    Yang R; Yin N; Zhao Y; Li D; Zhang X; Li X; Zhang Y; Faiola F
    Front Pharmacol; 2021; 12():772768. PubMed ID: 35046808
    [No Abstract]   [Full Text] [Related]  

  • 16. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
    Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 18. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
    Li Z; Guo C; Liu X; Qiu Z; Zhang R
    Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.
    Feng Z; Li X; Tong WK; He Q; Zhu X; Xiang X; Tang Z
    Front Pharmacol; 2022; 13():894685. PubMed ID: 36506552
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
    Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
    Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.